TABLE 4.
Multivariate model of factors predicting CPM
| OR | p-value | 95 % CI | |
|---|---|---|---|
| Subtype | |||
| HER2-positive/HR-positive | 1.02 | 0.624 | 0.94–1.11 |
| HER2-positive/HR-negative | 0.98 | 0.705 | 0.87–1.10 |
| HER2-negative/HR-positive | Ref | ||
| TNBC | 1.26 | <0.001 | 1.16–1.37 |
| Reconstruction | |||
| No | Ref | ||
| Yes | 2.62 | <0.001 | 2.48–2.78 |
| Age | |||
| <40 | 2.41 | <0.001 | 2.19–2.65 |
| 40–49 | 1.46 | <0.001 | 1.36–1.57 |
| 50–59 | Ref | ||
| 60–69 | 0.69 | <0.001 | 0.64–0.75 |
| 70–79 | 0.36 | <0.001 | 0.32–0.41 |
| ≥80 | 0.12 | <0.001 | 0.09–0.15 |
| Stage | |||
| I | Ref | ||
| II | 0.85 | <0.001 | 0.80–0.91 |
| III | 0.81 | <0.001 | 0.75–0.88 |
| Marital status | |||
| Married | Ref | ||
| Single | 0.82 | <0.001 | 0.75–0.88 |
| Separated | 0.92 | 0.034 | 0.86–0.99 |
| Race | |||
| White | Ref | ||
| Black | 0.48 | <0.001 | 0.43–0.53 |
| Other | 0.46 | <0.001 | 0.41–0.51 |
| Hispanic | |||
| No | Ref | ||
| Yes | 0.50 | <0.001 | 0.46–0.55 |
| Year of diagnosis | |||
| 2010 | Ref | ||
| 2011 | 1.15 | <0.001 | 1.09–1.21 |
Includes those with unilateral disease who received a mastectomy
CPM contralateral prophylactic mastectomy, OR odds ratio, CI confidence interval, HER2 human epidermal growth factor receptor-2, HR hormone receptor, TNBC triple-negative breast cancer